None
Quote | Annovis Bio Inc. (OTCMKTS:ANVS)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.015 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Annovis Bio Inc. (OTCMKTS:ANVS)
The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12%...
Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of ...
Message Board Posts | Annovis Bio Inc. (OTCMKTS:ANVS)
Subject | By | Source | When |
---|---|---|---|
Price trading | Bayutiger | investorshub | 05/10/2023 10:18:17 PM |
$ANVS The gaining last up | quieter | investorshub | 05/09/2023 5:35:44 AM |
Do we have a winner?Turn around time? | king koopa | investorshub | 05/04/2023 11:45:44 PM |
MomentumIts now | whytestocks | investorshub | 05/01/2023 8:12:02 PM |
$ANVS great article | McMagyar | investorshub | 04/29/2023 2:18:44 AM |
News, Short Squeeze, Breakout and More Instantly...
The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12%...
Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of ...
Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food an...